Immunogenic cell death (ICD) plays a relevant role in tumor immunotherapy and is characterized by the secretion of damage-associated molecular patterns (DAMPs), including the release of adenosine triphosphate (ATP), exposure of cell membrane surface calreticulin (CRT) and secretion of high mobility group protein B1 (HMGB1) [14, 15]. The gene discussed is HMGB1; the disease is neoplasm.